Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559585 · ClinicalTrials.gov registry record · Phase 3
Methotrexate-Inadequate Response Study
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,492
- Enrollment target
NCT00559585: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00559585 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 2,492 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (223% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00559585, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,492 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.
Primary Outcome
The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
Interventions
- DRUG Subcutaneous (SC) Abatacept
- DRUG Intravenous (IV) Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,492 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
What the finished NCT00559585 record still lists
NCT00559585 is an interventional study that assigns participants to a tested intervention. Its 2,492 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (223% higher).
The record links to 0 conditions, and to 2 interventions - of which Subcutaneous (SC) Abatacept is the first listed.
NCT00559585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00559585 about?
NCT00559585 is a clinical study titled "Methotrexate-Inadequate Response Study". The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.
What is the current status of trial NCT00559585?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,492 participants. The study started on 2008-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00559585?
The interventions under investigation include: Subcutaneous (SC) Abatacept (DRUG), Intravenous (IV) Abatacept (DRUG).
Who is sponsoring clinical trial NCT00559585?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00559585's enrollment target sits among peer trials
2,492 88th of 2000 higher than 1,913 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia